<code id='DA1D60B2BF'></code><style id='DA1D60B2BF'></style>
    • <acronym id='DA1D60B2BF'></acronym>
      <center id='DA1D60B2BF'><center id='DA1D60B2BF'><tfoot id='DA1D60B2BF'></tfoot></center><abbr id='DA1D60B2BF'><dir id='DA1D60B2BF'><tfoot id='DA1D60B2BF'></tfoot><noframes id='DA1D60B2BF'>

    • <optgroup id='DA1D60B2BF'><strike id='DA1D60B2BF'><sup id='DA1D60B2BF'></sup></strike><code id='DA1D60B2BF'></code></optgroup>
        1. <b id='DA1D60B2BF'><label id='DA1D60B2BF'><select id='DA1D60B2BF'><dt id='DA1D60B2BF'><span id='DA1D60B2BF'></span></dt></select></label></b><u id='DA1D60B2BF'></u>
          <i id='DA1D60B2BF'><strike id='DA1D60B2BF'><tt id='DA1D60B2BF'><pre id='DA1D60B2BF'></pre></tt></strike></i>

          Home / fashion / hotspot

          hotspot


          hotspot

          author:focus    Page View:86865
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In